OncoSil Medical Ltd ( (AU:OSL) ) has shared an announcement.
OncoSil Medical Limited has appointed Nathan Jong as the new Company Secretary, succeeding Christian Dal Cin. Nathan Jong, with his extensive experience in corporate secretarial and finance roles within the life sciences sector, will handle communication with the ASX regarding listing rule matters. This appointment is expected to strengthen OncoSil’s operational framework as it continues to commercialize its innovative pancreatic cancer treatment device globally.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a company specializing in the development of cancer treatment devices, specifically the OncoSil™ brachytherapy device. This device is a key component in the treatment of locally advanced unresectable pancreatic cancer, a condition with a poor prognosis due to late-stage diagnosis. The OncoSil™ device delivers targeted intratumoural placement of Phosphorous-32 in combination with chemotherapy and has received breakthrough device designation in the EU, UK, and US. It is approved for sale in over 30 countries, with initial treatments conducted in Spain, Italy, and Israel.
Technical Sentiment Signal: Buy
Current Market Cap: A$23.03M
Learn more about OSL stock on TipRanks’ Stock Analysis page.